Lifesci Acquisition II Corp.

Completed 2021-10-06
  • CIK 1819113
  • LSAQ
  • Now SNCE
  • IPO 2020-11-23
  • $80.1M trust
  • 284 filings

Successfully merged with Science 37, Inc. • Now trading as SNCE

IPO Size
$80.1M
raised at the IPO
Trust
$80.1M
as of 2021-09-30
Current Status
Completed
from its latest filing
IPO Year
2020
year it listed

Filings, by quarter

284 filings over 15 quarters; violet bars carry a milestone

  1. 20 Q3: 1 filing
  2. 20 Q4: 26 filings
  3. 21 Q1: 5 filings
  4. 21 Q2: 7 filings
  5. 21 Q3: 16 filings
  6. 21 Q4: 57 filings
  7. 22 Q1: 21 filings
  8. 22 Q2: 24 filings
  9. 22 Q3: 17 filings
  10. 22 Q4: 13 filings
  11. 23 Q1: 15 filings
  12. 23 Q2: 26 filings
  13. 23 Q3: 7 filings
  14. 23 Q4: 9 filings
  15. 24 Q1: 40 filings
  • S-1 filed 20 Q3
  • IPO 20 Q4
  • Definitive agreement 21 Q2
  • Completed 21 Q4

SPAC Overview

Where it stands on the road from S-1 to merger

Timeline Progress

About

LifeSci Acquisition II Corp. is a blank-check company formed to complete an initial business combination. It intends to target healthcare-innovation companies, including those developing biopharma, medical technology, digital health, and healthcare services assets.

Investment Focus

Biopharmaceuticals, Healthcare, Technology

Geographic Focus

North America, Europe

Key Information

As the filings state it

IPO Date
2020-11-23
Total Redemptions
$23M
PIPE
$200M
Jurisdiction of Incorporation
Delaware
SIC
6770
Completion Date
2021-10-06
Merger Target
Science 37, Inc.
SPAC Ticker
LSAQ
Merged Ticker
SNCE

SPAC Team

The banks on its IPO, and the team as the filings describe it

Underwriters

Extended Team Information

The team is led by Andrew McDonald and Michael Rice, co-founders of LifeSci Advisors and LifeSci Capital, and David Dobkin, managing director of LifeSci Capital. The filing describes the LifeSci team as having life-sciences investing and banking, scientific, medical, legal, and operational experience.

External Resources